Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sirukumab - Janssen Biotech

Drug Profile

Sirukumab - Janssen Biotech

Alternative Names: CNTO-136; PLIVENSIA™; Shirukumabu

Latest Information Update: 25 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Centocor
  • Developer Centocor; GlaxoSmithKline; Janssen Biotech
  • Class Antiasthmatics; Antidepressants; Antirheumatics; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II COVID 2019 infections
  • Preregistration Submission Withdrawal Rheumatoid arthritis
  • Discontinued Asthma; Atherosclerosis; Giant cell arteritis; Lupus nephritis; Major depressive disorder

Most Recent Events

  • 24 Jun 2021 Janssen Pharmaceutica completed a phase II trial in COVID-2019 infections (Adjuvant therapy) in USA (IV) (NCT04380961)
  • 12 Apr 2021 Discontinued - Phase-II for Asthma in Spain, USA (SC) before April 2021 (Janssen Biotech website, April 2021)
  • 12 Apr 2021 Discontinued - Phase-II for Lupus nephritis in Belgium, Mexico, Netherlands, Poland, Thailand, USA (IV) before April 2021 (Janssen Biotech website, April 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top